

Latex allergy

ImmunoCAP™ Specific IgE tests

Latex allergy is one of the significant allergies associated with occupational exposure and groups at higher risk may include health care workers (HCW), children with spina bifida and individuals with multiple surgeries. Latex allergy can trigger contact urticaria but also severe and even life-threatening allergic reactions.¹⁻²

ImmunoCAP™ Whole Allergen


ImmunoCAP™ Allergen Components



Good to know!

It has been reported that 30% to 50% of latex-allergic patients present with syndrome derived as “**Latex-fruit**”, which is a cross-reactivity observed between latex and fresh fruits.^{1,9}

The fruits and vegetables most commonly associated with this syndrome include avocado, banana, chestnut, and kiwi.^{1,9}



ImmunoCAP Whole allergen	Latex (k82)						
ImmunoCAP Allergen components	Primary allergens				Cross-reactive allergens		Other
	Hev b 1 (k215)	Hev b 3 (k217)	Hev b 5 (k218)	Hev b 6.02 (k220)	Hev b 11 (k224)	Hev b 8 (k221)	MUXF3 (CCD)* (o214)
Positive results and relevant latex allergy	Likely Associated with severe reaction during surgery ^{3,4}		Likely Associated with urticaria, angioedema, rhinitis, asthma ^{1,3,6,7}		Unlikely Associated with oral allergy syndrome (OAS), rhinoconjunctivitis, angioedema ⁸⁻¹¹		Unlikely Associated with low or no clinical relevance
Patient management	Latex avoidance		Latex avoidance Information on latex / cross- reactivity to plant foods		Latex avoidance not necessary** Info on cross-reactivity to plant foods/profilin		No impact

Results should always be interpreted in the context of the clinical history. * Latex positivity (k82) can also be explained by IgE antibodies against cross-reactive carbohydrate determinants (CCD) and can be detected with MUXF3 ** with precaution

References: 1. Dramburg S, et al. *Pediatr Allergy Immunol* 2023;34(Suppl 28):e13854. 2. Parisi CAS, et al. *World Allergy Organ J* 2021;14(8):100569. 3. Wagner B, et al. *J Allergy Clin Immunol* 2001;108(4):621-627. 4. Kleine-Tebbe J, et al. 2017. *Editors: Molecular Allergy Diagnostics*. Springer International Publishing Switzerland. 5. Caballero ML, et al Expert review of clinical immunology 2015;11(9):977-992. 6. Raulf-Heimsoth M, et al. *Allergy* 2004;59(7):724-733. 7. Vandenplas O, et al. *Allergy* 2016;71:840– 849. 8. Ebo DG, et al. *Clin Exp Allergy* 2010;40(2):348-358. 9. Schuler S, et al. *Clin Transl Allergy* 2013;3(1):11. 10. Ott H, et al. *J Invest Allergol Clin Immunol* 2010;20(2):129-138. 11. Garnier L, et al. *Eur Ann Allergy Clin Immunol* 2012;44(2):73–79.

Official product names: ImmunoCAP Allergen k82, Latex; ImmunoCAP Rare Allergen k215, Allergen component rHev b 1 Latex; ImmunoCAP Rare Allergen k217, Allergen component rHev b 3 Latex; ImmunoCAP Allergen k218, Allergen component rHev b 5 Latex; ImmunoCAP Rare Allergen k220, Allergen component rHev b 6.02 Latex; ImmunoCAP Rare Allergen k221, Allergen component rHev b 8 Profilin, Latex; ImmunoCAP Rare Allergen k224, Allergen component rHev b II Latex; ImmunoCAP Allergen o214, Allergen component MUXF3 CCD, Bromelain

 Learn more at thermofisher.com/allergencomponents

© 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Legal manufacturer: Phadia AB (a part of Thermo Fisher Scientific). 453351.AL.EU7.EN.V1.25